The potential US implementation of a 100% tariff on imported pharmaceuticals could pose a significant disruption for Indian contract development and manufacturing organizations (CDMOs) such as Piramal Pharma, Glenmark, and Sun Pharma. This could lead to market uncertainties for these key players in the pharma industry.

Adani Power, Cochin Shipyard, Hyundai Motor India, among others, will now be available for trading in the Futures & Options segment as of April 1. Conversely, HUDCO, Piramal Pharma, Tata Technologies, and Torrent Power have withdrawn from the F&O market, with differing stock lot sizes per company.

Piramal Pharma's subsidiary has secured Kenalog, a significant addition to their global generic medications portfolio, from Bristol-Myers Squibb. This expansion is expected to strengthen their presence in the US, Europe, and Asia-Pacific markets for complex hospital generics.